908 Devices, Inc. (MASS)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$10.05+0.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · MASS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 22.9% |
| Our one-year growth estimate | diamond | 26.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 8 industry peers · Company calendar date is not available
MASS — capital allocation — Pursuant to the terms of the Purchase
Dated 2026-05-06
Pursuant to the terms of the Purchase Agreement and as set forth in Item 1.01, the Company issued or may issue Company Shares as Option Share Payment, Stock Consideration and Earn-Out Consideration (subject to the achievement of certain milestones set forth in the Purchase Agreement) (such Company Shares, the “Transaction Shares”). The Transaction Shares were or will be issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exempt…
Why it matters: Growth in the installed base shows strong demand for products and future income potential.
Supportive ifInstalled base grows by 20% year over year in Q2.
Worry ifInstalled base growth drops below 20% year over year in Q2.
Why it matters: A smaller adjusted EBITDA loss means the company is more efficient. It shows better control of costs.
Supportive ifAdjusted EBITDA loss was below $(1.5) million in Q3.
Worry ifAdjusted EBITDA loss remains at or above $(1.9) million in Q3.
Why it matters: Strong sales of VipIR support the company's growth strategy and revenue outlook.
Supportive ifSales of VipIR exceed 50 units in Q3.
Worry ifSales of VipIR fall below 30 units in Q3.
Why it matters: Integrating NIRLAB could help make more money and reach more customers.
Supportive ifManagement gives updates on how well they are integrating NIRLAB. They also share how much money they are making from it.
Worry ifIntegration problems may cause delays or less money from NIRLAB than expected.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$217 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $559 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,437 loss on $10,000 · 44.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If healthcare revenue growth speeds up, it could lift 908 Devices' prospects. This would signal a healthier market environment.
Supportive ifHealthcare sector revenue growth speeds up toward 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: More recurring revenue shows strong customer loyalty and growth in subscriptions. This is important for stability.
Supportive ifRecurring revenue was above $4.9 million for Q3, making up over 30% of total revenue.
Worry ifRecurring revenue was below $4.0 million for Q3, making up less than 30% of total revenue.
Why it matters: Higher operating income shows good cost control and efficiency. This matters for long-term success.
Supportive ifOperating income shows a positive change from Q1 2026.
Worry ifOperating income keeps falling or stays negative in Q2 2026.
Why it matters: If NIRLAB integrates well, it could increase revenue. It may also help in narcotics detection.
Supportive ifManagement says more than 30 agencies want NIRLAB products.
Worry ifNo updates or signs of interest in NIRLAB products show poor integration.
Why it matters: The NIRLAB purchase could increase steady income. This is important for the company's growth.
Supportive ifSteady income rose to over 30% of total income in Q2.
Worry ifRecurring revenue falls below 30% of total revenues in Q2.
Why it matters: Staying within this range confirms management's growth strategy is on track. It shows they can maintain momentum after a strong Q2.
Supportive ifQ3 revenue grew by 21% to 25% compared to last year.
Worry ifQ3 revenue grew by less than 21% compared to last year.
Why it matters: Higher operating income is key for the company's financial health. It also builds trust with investors.
Supportive ifOperating income improves to less than -$10 million in Q2.
Worry ifOperating income fell below -$12.88 million in Q2.
Why it matters: Confirming the revenue growth guidance is key to investor confidence. It shows the company is on track.
Supportive ifQ2 revenue growth guidance remains in the range of 19% to 25% year over year.
Worry ifGuidance for Q2 revenue growth drops below 19% year over year.